BRIEF—BiomX appoints chief development officer

Israeli microbiome specialist BiomX has appointed Merav Bassan, formerly VP and head of translational sciences at Teva Pharmaceutical, as chief development officer.

The firm is developing both natural and engineered phage therapies, and is working to advance its lead programs into the clinic.

Dr Bassan was also previously VP and president of project leadership at Teva, overseeing end-to-end drug development at pre-clinical, Phase I to III and post marketing stages in multiple therapeutic areas.

Chief executive Jonathan Solomon said her experience, “including in relevant therapeutic areas such as gastrointestinal and oncological therapies,” was: “particularly well-matched to BiomX as we enter this new stage in our development.”